3,3′,5-tetraiodothyroacetic acid | 92151-30-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,3′,5-tetraiodothyroacetic acid
• 英文别名: Triac；4-(4'-Hydroxy-3',5'-diiodphenoxy)-3-iod-phenylessigsaeure；[4-(4-hydroxy-3,5-diiodo-phenoxy)-3-iodo-phenyl]-acetic acid；[4-(4-Hydroxy-3,5-dijod-phenoxy)-3-jod-phenyl]-essigsaeure；3,3',5'-triiodo-thyroacetic acid；3,5,3'-triiodothyroacetic acid；2-[4-(4-Hydroxy-3,5-diiodophenoxy)-3-iodophenyl]acetic acid
• CAS: 92151-30-9
• 化学式: C₁₄H₉I₃O₄
• 分子量: 621.937
• InChiKey: XLWNVHQIKWRWOE-UHFFFAOYSA-N

物化性质

• 熔点：
  220 °C
• 沸点：
  501.3±50.0 °C(Predicted)
• 密度：
  2.466±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-(4-氯甲基-2-碘-苯氧基)-4-甲氧基-苯 在 ammonium hydroxide 、 sodium hydroxide 、 乙醇 、 乙二醇甲醚 、 氢碘酸 、 碘 、 溶剂黄146 作用下， 生成 3,3′,5-tetraiodothyroacetic acid
  参考文献：
  名称：

  Roche et al., Bulletin de la Societe Chimique de France, 1959, p. 715

  摘要：

  DOI：

文献信息

• Uses of formulations of thyroid hormone antagonists and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells
  申请人：Ordway Research Institute, Inc.

  公开号：EP2662079A1

  公开（公告）日：2013-11-13

  Disclosed are methods of increasing the chemosensitivity of normal and/or chemoresistant tumor or cancer cells using thyroid hormone antagonists and/or nanoparticulate or polymeric forms thereof. Also disclosed are methods of increasing radiosensitivity of normal and/or radioresistant tumor or cancer cells using thyroid hormone antagonists and/or nanoparticulate or polymeric forms thereof.

  公开了使用甲状腺激素拮抗剂和/或其纳米粒子或聚合物形式来增加正常和/或化疗耐药肿瘤或癌细胞的化疗敏感性的方法。还公开了使用甲状腺激素拮抗剂和/或其纳米粒子或聚合物形式来增加正常和/或放射治疗耐药肿瘤或癌细胞的放射敏感性的方法。
• USES OF FORMULATIONS OF THYROID HORMONE ANALOGS AND NANOPARTICULATE FORMS THEREOF TO INCREASE CHEMOSENSIVITY AND RADIOSENSITIVITY IN TUMOR OR CANCER CELLS
  申请人：Davis Paul J.

  公开号：US20120315320A1

  公开（公告）日：2012-12-13

  Disclosed are methods of increasing the chemosensitivity of normal and/or chemoresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof. Also disclosed are methods of increasing radiosensitivity of normal and/or radioresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof.

  本发明揭示了使用甲状腺激素类似物及其纳米粒子或聚合物形式，增加正常和/或化疗耐药肿瘤或癌细胞的化疗敏感性的方法。本发明还揭示了使用甲状腺激素类似物及其纳米粒子或聚合物形式，增加正常和/或放射线耐药肿瘤或癌细胞的放射线敏感性的方法。
• Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
  申请人：Mousa Shaker A.

  公开号：US20090022806A1

  公开（公告）日：2009-01-22

  Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

  本发明涉及治疗与血管生成有关的疾病的方法，包括向受试者施用有效量的聚合物纳米粒子形式的甲状腺激素激动剂、部分激动剂或其拮抗剂，以促进或抑制受试者的血管生成。本发明还涉及聚合物形式的甲状腺激素或甲状腺激素类似物的组合物。
• NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF
  申请人：Davis Paul J.

  公开号：US20110052715A1

  公开（公告）日：2011-03-03

  Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Nanoparticle forms of thyroid hormone or thyroid hormone analogs as well as uses thereof are also disclosed.

  本发明涉及治疗与血管生成相关的疾病的方法，包括向患者施用有效量的聚合物纳米粒子形式的甲状腺激素激动剂、部分激动剂或其拮抗剂，以促进或抑制患者体内的血管生成。本发明还揭示了甲状腺激素或甲状腺激素类似物的纳米粒子形式以及其用途。
• Nanoparticle and Polymer Formulations for Thyroid Hormone Analogs, Antagonists, and Formulations and Uses Thereof
  申请人：Davis Paul J.

  公开号：US20110142941A1

  公开（公告）日：2011-06-16

  Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

  揭示了治疗与血管生成相关疾病的方法，包括给予有效量的聚合物纳米粒子形式的甲状腺激素激动剂、部分激动剂或其拮抗剂，以促进或抑制受试者的血管生成。还揭示了聚合物形式的甲状腺激素或甲状腺激素类似物的组成。